Core Insights - Phio Pharmaceuticals' INTASYL compound PH-762 has been awarded the 2025 Immunomodulatory Solution of the Year by the BioTech Breakthrough Awards Program, highlighting its significance in cancer treatment [1][2][3] Company Overview - Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology aimed at eliminating cancer [1][4] - The company's lead clinical program, PH-762, targets the PD-1 gene associated with various skin cancers and is currently undergoing a Phase 1b trial for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [4] Industry Recognition - The BioTech Breakthrough Awards program is an independent initiative that recognizes outstanding achievements in life sciences and biotechnology globally, with a focus on innovative solutions and products [2][9] - The award received by PH-762 underscores its potential as a non-surgical treatment option for patients with cutaneous carcinomas, addressing a significant medical need [3]

Core Viewpoint - Phio Pharmaceuticals Corp. has announced the exercise of warrants that will generate approximately $13.4 million in gross proceeds, aimed at advancing its clinical development activities for its lead product, PH-762, targeting skin cancers [1][4]. Group 1: Warrant Exercise Details - The company has entered into agreements to exercise warrants for a total of 5,663,182 shares of common stock, with exercise prices ranging from $2.00 to $5.45 per share [1]. - The exercise includes 60,000 shares at $2.00, 948,596 shares at $2.485, and 4,654,586 shares at a reduced price of $2.05 [1]. - The gross proceeds from these exercises are expected to be around $13.4 million before deducting fees and expenses [1]. Group 2: New Warrants and Offerings - In exchange for the immediate cash exercise of the warrants, holders will receive new unregistered warrants to purchase up to 8,855,248 shares of common stock [3]. - The offering will occur in two closings, with the first expected on or about November 4, 2025, and the second by November 18, 2025 [3]. - The new warrants will have an exercise price of $2.05 per share and will be immediately exercisable for a term of twenty-four months [3]. Group 3: Use of Proceeds - The net proceeds from the warrant exercises will primarily be used for working capital and to accelerate the completion of development activities for PH-762, following positive trial outcomes [4]. Group 4: Company Overview - Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on immuno-oncology therapeutics, utilizing its INTASYL® gene silencing technology [8]. - The lead clinical program, PH-762, targets the PD-1 gene and is currently in a Phase 1b trial for treating various skin cancers [8].

Core Insights - Phio Pharmaceuticals Corp. announced promising pathologic results from its ongoing Phase 1b trial for PH-762, showing 100% tumor clearance in one patient, over 90% in another, and over 50% in a third patient with cutaneous squamous cell carcinoma (cSCC) [2][3] - The trial has treated a total of 18 patients with cutaneous carcinomas, with cumulative results indicating six complete responses, two near complete responses, and two partial responses [3] - The Safety Monitoring Committee confirmed no dose-limiting toxicities or clinically relevant adverse effects at the maximum dose concentration, indicating a favorable safety profile for PH-762 [6][7] Company Overview - Phio Pharmaceuticals is a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology aimed at treating various forms of skin cancer [9] - The lead clinical program, PH-762, targets the PD-1 gene and is being evaluated for its potential as a non-surgical treatment for skin cancers, including cSCC, melanoma, and Merkel cell carcinoma [9] Trial Design and Results - The Phase 1b trial is designed to assess the safety and tolerability of intratumoral PH-762 in patients with Stages 1, 2, and 4 cSCC, Stage 4 melanoma, and Stage 4 Merkel cell carcinoma, with pathologic responses evaluated approximately five weeks post-injection [4] - The trial has shown no clinical progression of disease in any patients treated thus far, and additional patients may continue to be screened and treated as part of the fifth cohort [3][5]

Core Insights - Phio Pharmaceuticals has appointed Mr. David H. Deming as Lead Independent Director, bringing over 30 years of experience in investment banking and asset management to the role [1][2][3] Company Overview - Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology aimed at eliminating cancer [1][4] - The company's lead clinical program is PH-762, which targets the PD-1 gene associated with various skin cancers and is currently undergoing a Phase 1b trial for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [4] Leadership Experience - Mr. Deming has a significant background in investment banking, having spent over 27 years at JP Morgan, where he led the Health Group in investment banking for the last 12 years of his tenure [2] - His experience in the biopharma sector and corporate boards is expected to provide valuable insights as Phio advances its gene silencing technology [3]

Core Insights - Premarket trading is showing notable activity with early price movements indicating potential opportunities before the market opens [1] Premarket Gainers - Galaxy Payroll Group Limited (GLXG) increased by 39% to $5.34 - Lithium Americas Corp. (LAC) rose by 31% to $7.52 - Senmiao Technology Limited (AIHS) gained 22% to $2.45 - The AES Corporation (AES) saw a 10% increase to $14.53 - Strive, Inc. (ASST) also increased by 10% to $2.77 - Shoulder Innovations, Inc. (SI) rose by 9% to $13.78 - Top KingWin Ltd (WAI) increased by 8% to $3.80 - Southland Holdings, Inc. (SLND) saw a 7% increase to $4.61 - CaliberCos Inc. (CWD) rose by 6% to $4.75 - Mannatech, Incorporated (MTEX) increased by 5% to $10.53 [3] Premarket Losers - Real Messenger Corporation (RMSG) decreased by 16% to $2.01 - Etoiles Capital Group Co., Ltd (EFTY) fell by 14% to $14.45 - Enanta Pharmaceuticals, Inc. (ENTA) dropped by 13% to $10.41 - CollPlant Biotechnologies Ltd. (CLGN) saw an 11% decrease to $2.39 - Fortress Biotech, Inc. (FBIO) declined by 10% to $3.30 - Uni-Fuels Holdings Limited (UFG) fell by 9% to $7.52 - Alset Inc. (AEI) decreased by 9% to $2.30 - JFB Construction Holdings (JFB) saw a 5% decline to $12.20 - SHF Holdings, Inc. (SHFS) dropped by 5% to $6.80 - Phio Pharmaceuticals Corp. (PHIO) decreased by 5% to $2.34 [4]

Core Insights - Several healthcare and biotech stocks experienced significant price movements on September 29, driven by clinical trial updates, regulatory progress, and strategic announcements Company Performance Highlights - Phio Pharmaceuticals Corp. (PHIO) saw an 8.9% increase in after-hours trading, rising from $2.36 to $2.57, following a 5.83% gain during the regular session, attributed to a positive safety committee recommendation for its PH-762 skin cancer trial [1][2] - Barinthus Biotherapeutics plc (BRNS) rose 8.11% in after-hours trading to $1.60 after closing at $1.48, with a notable 21.3% gain, driven by renewed interest in its immunotherapeutic pipeline [2][3] - Neogen Corp. (NEOG) jumped 5.59% in after-hours trading to $5.90, reversing a 1.41% decline earlier in the day, following announcements of its upcoming earnings release and a renewed sponsorship agreement [3][4] - OKYO Pharma Ltd. (OKYO) increased by 9% in after-hours trading to $2.18 after a decline of 8.26% during the regular session, due to renewed focus on its clinical-stage program for urcosimod [5] - Aurinia Pharmaceuticals Inc. (AUPH) rose 8.05% in after-hours trading to $11.95, despite a 15.83% drop earlier, reflecting heightened activity around its lupus nephritis treatment, LUPKYNIS, and a collaboration with Otsuka Pharmaceutical [6] - RAPT Therapeutics, Inc. (RAPT) climbed 4.43% in after-hours trading to $27.80, following the FDA's clearance of its IND application for RPT904, allowing it to proceed with a Phase 2b trial targeting food allergies [7][8]

Core Viewpoint - Phio Pharmaceuticals is advancing its proprietary INTASYL® gene silencing technology aimed at treating skin cancers, with positive interim results reported from an ongoing Phase 1b clinical trial for its lead compound PH-762 [1][4]. Group 1: Company Overview - Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on immuno-oncology therapeutics [4]. - The company's lead clinical program, PH-762, targets the PD-1 gene associated with various skin cancers, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [4]. Group 2: Clinical Trial Progress - The ongoing Phase 1b dose escalation clinical trial for PH-762 has shown positive interim safety and efficacy results [1]. - PH-762 is being evaluated as a potential non-surgical treatment option for skin cancers [4]. Group 3: Upcoming Events - Phio Pharmaceuticals will participate in a live virtual non-deal roadshow hosted by Renmark Financial Communications on September 30, 2025, where CEO Robert Bitterman will present updates on the company's technology and clinical progress [2][3].

Core Insights - Phio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to combat cancer [1][4] - The company will present updates on its ongoing Phase 1b clinical trial for its lead product candidate PH-762 at the Life Sciences Future Conference on September 25-26, 2025 [1][2] Company Overview - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is advancing its INTASYL® gene silencing technology, particularly in the field of immuno-oncology [4] - The lead clinical program, PH-762, targets the PD-1 gene associated with various skin cancers, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [4] - The ongoing Phase 1b trial (NCT 06014086) is evaluating PH-762 as a potential non-surgical treatment for skin cancers [4] Conference Details - The presentation by Mr. Robert Bitterman, President and CEO, will include updates on the Phase 1b clinical trial and future strategies for the PH-762 development program [2] - The Life Sciences Future Conference will take place at the Sheraton Valley Forge Hotel in King of Prussia, PA, on September 25-26, 2025 [3]

Market Overview - U.S. equity markets experienced a dynamic session on September 10, 2025, with the S&P 500 and Nasdaq Composite reaching record highs, driven by positive inflation data and Oracle's strong earnings forecast [1][11] - The Dow Jones Industrial Average declined by 0.5% to 45,490.92 points, while the Russell 2000 index fell by 0.2% to 2,378.01, indicating mixed performance across major indexes [2] Key Market Catalysts - The August Producer Price Index (PPI) reported an unexpected 0.1% month-over-month decline, boosting investor confidence in a potential Federal Reserve interest rate cut [3] - Traders are anticipating at least a 25-basis-point rate reduction in September, with some speculating a 50-basis-point cut, as the 10-year Treasury yield fell below 4.05% [3] Corporate Highlights - Oracle's stock surged between 35.9% and 40.3% following its optimistic earnings forecast, projecting AI-powered cloud revenue to reach $144 billion by 2030 [4] - The potential $300 billion cloud computing deal with OpenAI further fueled Oracle's positive outlook, highlighting the growing demand for AI infrastructure [4] - Other AI-related companies, such as Nvidia, Broadcom, and Advanced Micro Devices, also saw stock increases due to Oracle's momentum [7][8] Upcoming Market Events - Investors are awaiting the U.S. Consumer Price Index (CPI) report on September 11, 2025, which is crucial before the Federal Reserve's policy meeting on September 16-17 [5] - The Treasury will conduct a 30-year bond auction, and a "triple witching" event is expected to increase market volatility [6] Notable Stock Movements - Klarna's IPO saw a strong debut, rising 14.6% to 16% [14] - GameStop shares increased by 6.21% after reporting better-than-expected second-quarter results [14] - Johnson Controls International Plc raised its quarterly cash dividend, leading to a 3% increase in its stock price [14] - However, Synopsys experienced a significant decline of 34% to 35.8% after forecasting lower-than-expected earnings [14] - Chewy's stock dropped over 15% despite reporting better-than-expected results, indicating market disappointment [14] - Apple shares fell 3.2% after unveiling its iPhone 17 models, as analysts noted a lack of significant surprises [14]

Core Insights - Biotech stocks experienced significant gains in after-hours trading on September 9, 2025, driven by clinical updates, insider buying, and investor conference appearances across several small- and mid-cap companies [1] Company Summaries - **Immutep Ltd. (IMMP)**: Shares rose by 4.37% to $1.67 after-hours, following a decline of 6.98% during regular trading. The stock's rebound was fueled by the acceptance of data from its EFTISARC-NEO Phase II trial for oral presentation at CTOS 2025, focusing on a rare cancer with high unmet need [2][3] - **Nautilus Biotechnology Inc. (NAUT)**: Shares surged by 12.25% to $0.7521 after-hours, recovering from a 4.42% decline in regular trading. The increase was attributed to insider buying by CEO Sujal M. Patel, who purchased 83,500 shares, signaling confidence in the company [4][5] - **Pliant Therapeutics Inc. (PLRX)**: The stock ended regular trading at $1.75, up 1.16%, and jumped 16.00% to $2.03 after-hours. The upcoming third-quarter earnings report on November 6, 2025, is expected to provide updates on its lead candidate targeting idiopathic pulmonary fibrosis [6][7] - **Jin Medical International Ltd. (ZJYL)**: Shares closed at $0.6532, gaining 3.65% during regular trading and rising 7.15% to $0.6999 after-hours. The catalyst for this movement was the announcement of expanded production capabilities in China, aimed at enhancing global delivery of medical equipment [7][8] - **Phio Pharmaceuticals Corp. (PHIO)**: The stock rose 8.20% to $2.64 after-hours, building on a 13.49% increase during regular trading. The momentum was driven by participation in the H.C. Wainwright 27th Annual Global Investment Conference, where updates on its Phase 1b clinical trial for PH-762 will be presented [8][9] - **Kura Oncology Inc. (KURA)**: Shares increased by 6.12% to $8.50 after-hours, following a 1.60% decline in regular trading. The rally was linked to the company's presentation at the H.C. Wainwright conference, highlighting key developments and upcoming regulatory milestones for Ziftomenib [10][11][12]